
The National Institute for Health and Care Excellence (NICE) has endorsed a non-hormonal medication for addressing moderate to severe menopausal hot flashes and night sweats, making it available through England’s NHS. The guidance, released in its final form on March 11, 2026, cleared fezolinetant (Veoza), a daily 45-milligram tablet developed by Astellas Pharma, which interrupts brain signals responsible for triggering these symptoms.
This treatment is intended for individuals who either cannot use hormone replacement therapy (HRT) or prefer not to. For instance, HRT may be ruled out in patients with a history of deep-vein thrombosis or pulmonary embolism.
Eligibility and Safety
The recommendation also allows consideration of the drug following a clinical risk evaluation for patients with certain diabetes or cardiovascular conditions. However, NICE explicitly excludes those currently battling breast cancer, other estrogen-sensitive tumors, or liver disorders. For survivors of breast cancer or estrogen-dependent malignancies who have finished treatment, a personalized assessment is necessary before prescribing fezolinetant, as clinical trial data involving this group remains incomplete. Regular liver function tests are mandatory before and during treatment.
Reaction to the Decision
Helen Knight, NICE’s director of medicines evaluation, stated, “Menopausal hot flushes and night sweats can deeply disrupt daily life and overall health. For those unable to use HRT, whether due to medical reasons or personal choice, treatment options have been severely limited until now.”
She added that “the available evidence confirms fezolinetant effectively reduces symptoms while proving cost-efficient, delivering value for public funds. This approval will finally provide relief for many who have no viable alternatives to HRT.”
Christina Nurmahi, lead pharmacist for women and newborn services at University Hospital Southampton, called the decision “excellent news and long overdue.” She emphasized that managing vasomotor symptoms in women excluded from HRT has long presented significant challenges, and this new non-hormonal alternative will benefit numerous patients.
Nuttan Tanna, a women’s health and osteoporosis consultant pharmacist at London North West University Healthcare NHS Trust, noted that women avoiding HRT often resort to antidepressants, such as SSRIs, SNRIs, gabapentin, or clonidine, to manage symptoms. While these medications may help, he observed that HRT remains superior for its broader health advantages, including bone density protection alongside symptom relief.
Paul Simpson, chair-elect of the British Menopause Society, remarked, “Although hormonal treatments suit many women, they are not appropriate for everyone. Providing NHS-funded access to this new non-hormonal drug class will address unmet needs in symptom management. The potential benefits of this medication have been anticipated for years, and its long-awaited approval will bring much-needed support to those who need it most.”